WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 21, 2005-- -- Supplemental New Drug Application seeks marketing approval for five-day treatment of acute bacterial sinusitis and community-acquired pneumonia -- Oscient Pharmaceuticals (Nasdaq: OSCI) has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of FACTIVE(R) (gemifloxacin mesylate) tablets (320 mg once-daily) for the five-day treatment of acute bacterial sinusitis (ABS) and the five-day treatment of mild to moderate community-acquired pneumonia (CAP). FACTIVE is currently approved by the FDA for the five-day treatment of acute bacterial exacerbations of chronic bronchitis (AECB) and the seven-day treatment of mild to moderate CAP.